In In re Teva Securities Litigation, Eric Gaier was retained on behalf of Teva Pharmaceuticals to analyze allegations by class plaintiffs that certain Teva executives misrepresented the source of Teva’s profit success and the competitive nature of markets for generic drugs. Dr. Gaier testified on antitrust issues associated with alleged collusion in generic drug markets and the sources of Teva’s profits.
The team
Partner
Partner
Partner
Partner
Partner
The team also includes
- Manager
- Manager
